Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 433 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Long Term Follow-up Clear all
Active, not recruiting No phase listed Observational

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

NCT06162585
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy product-MCO-010
Biological
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 2, 2026, 10:34 PM EDT
Active, not recruiting No phase listed Observational

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

NCT00443274
View directory record Official record
Conditions
Breast Implant
Interventions
NBIR - US National Breast Implant Registry, 410 Arm, BIFs - Breast Implant Follow-Up Study
Other · Device
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
56,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2029
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 2, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

NCT04629521
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Cataract
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 2, 2026, 10:34 PM EDT
Completed No phase listed Observational

CART-meso Long-term Follow-up

NCT02388828
View directory record Official record
Conditions
Subjects Who Have Received Lentiviral-based CART-meso Therapy
Interventions
lentiviral-based CART meso therapy
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 2, 2026, 10:34 PM EDT
Terminated No phase listed Observational

A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02

NCT04836377
View directory record Official record
Conditions
Type 1 Gaucher Disease
Interventions
Safety and efficacy assessments
Other
Lead sponsor
AVROBIO
Industry
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Iowa City, Iowa • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 2, 2026, 10:34 PM EDT
Not listed Phase 4 Interventional

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

NCT04245436
View directory record Official record
Conditions
Anxiety, Depressive Symptoms
Interventions
Duloxetine, Escitalopram
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 2, 2026, 10:34 PM EDT
Completed No phase listed Observational

Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)

NCT00001612
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 10:34 PM EDT
Enrolling by invitation No phase listed Observational

5-Year Postoperative Outcomes of Patients Who Completed the CREST Study

NCT07480343
View directory record Official record
Conditions
Open-angle Glaucoma (OAG)
Interventions
CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
Procedure
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Active, not recruiting Phase 3 Interventional

Avelumab Program Rollover Study

NCT03815643
View directory record Official record
Conditions
Solid Tumors
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Spring Hill, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 2, 2026, 10:34 PM EDT
Recruiting Phase 3 Interventional

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Interventions
Cantharidin
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Saint Augustine, Florida • Plainfield, Indiana • Boardman, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354
View directory record Official record
Conditions
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
Interventions
CLBR001 and SWI019
Combination Product
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Duarte, California • San Diego, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Completed No phase listed Observational

Ceramic On Ceramic (COC) 36mm PAS IDE Rollover Subjects; Ceramic Acetabular Bearing With Ceramic Femoral Head in Total Hip Replacement

NCT02096198
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Post-Traumatic Osteoarthritis of Hip
Interventions
Not listed
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
20 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Sacramento, California • Denver, Colorado • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 2, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 2, 2026, 10:34 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Not yet recruiting No phase listed Observational

Understanding the Long-term Impact of COVID-19 in Adults

NCT07498504
View directory record Official record
Conditions
Long COVID, Long Covid19
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
5,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Active, not recruiting No phase listed Observational

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

NCT05714514
View directory record Official record
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 2, 2026, 10:34 PM EDT
Recruiting No phase listed Observational

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT07700966
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Prademagene Zamikeracel
Combination Product
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Completed No phase listed Observational Results available

ROOBY Trial Follow-up Extension

NCT01924442
View directory record Official record
Conditions
All Cause Mortality, MACE
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Northport, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 2, 2026, 10:34 PM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow up of the LTOG Cohort

NCT04787822
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Active, not recruiting No phase listed Observational

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05981131
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
N803 plus Bacillus Calmette-Guerin (BCG)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

NCT00451022
View directory record Official record
Conditions
Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Recruiting Phase 4 Interventional

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 10:34 PM EDT
Completed No phase listed Observational

LENS - Long-term Eltrombopag Observational Study

NCT00643929
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 2, 2026, 10:34 PM EDT